Background and objectives: The aim of the investigation presented here was to compare the rates, causes, and timing of cardiovascular (CV) death in incident peritoneal dialysis (PD) and hemodialysis (HD) patients.
C ardiovascular disease (CVD) represents the leading cause of death in dialysis patients, accounting for up to 40% of deaths in Australia, New Zealand, and the United States (1, 2) . Individuals with chronic kidney disease (CKD) have up to a 10-to 20-fold greater risk of cardiac death than age-and sex-matched controls without CKD (3, 4) . Once dialysis patients develop cardiac events, they are significantly less likely to receive important interventions and are far more likely to die than patients without CKD (5) .
The increased incidence of CVD in dialysis patients is only partially explained by an increased prevalence of traditional risk factors, such as hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, and physical inactivity (6, 7) . Additional risk may be conferred by nontraditional factors that are frequently observed in advanced CKD, such as hyperhomocysteinemia, anemia, abnormal calcium/phosphate metabolism, inflammation, malnutrition, oxidative stress, and elevated lipoprotein(s) (6,8 -11) .
There is limited evidence that dialysis modality may also influence CVD risk. Bleyer et al. (12) observed an increased risk of cardiac death in hemodialysis (HD) patients immediately after weekends, possibly related to the more frequent occurrence of hyperkalemia and fluid overload at this time. In contrast, the continuous nature of peritoneal dialysis (PD) may potentially minimize cardiovascular risk related to fluctuations in body fluid and electrolyte compositions. HD patients may also be exposed to a greater risk of CVD compared with PD patients as a result of more rapid loss of residual renal function (13, 14) and more hyperdynamic circulation conferred by the presence of an arteriovenous fistula and extracorporeal circulation (15) . On the other hand, PD patients are exposed to greater amounts of glucose in dialysate, leading to a much higher prevalence of insulin resistance, dyslipidemia, and metabolic syndrome (16) . There is also evidence that PD patients exhibit greater coagulability, possibly related to dyslipidemia (17) . Despite observed differences in known CVD risk factors between PD and HD patients, there has been little study to date of the influence of dialysis modality on CVD risk. Kennedy et al. (6) observed that PD was of borderline statistical significance (P ϭ 0.06) as an independent predictor of carotid atherosclerosis in stage 5 CKD. Previous registry studies have shown conflicting results with respect to the influence of dialysis modality on all-cause mortality (reviewed in reference 18), but none have specifically examined cardiovascular mortality. Moreover, many of these studies have suffered from serious limitations, such as inclusion of prevalent patients, use of proportional versus nonproportional hazards models, single-center design, data coding ambiguity, use of outdated data, dialysis modality selection bias, lack of adjustment for demographic and clinical variables, and residual confounding (18) . The aim of the study presented here was to evaluate the effects of dialysis modality on the frequency, types, and causes of cardiovascular mortality in a large, incident, ESRD population.
Patients and Methods
The study included all adult ESRD patients in Australia and New Zealand who were older than 18 yr and commenced dialysis between January 1, 1997 and December 31, 2007. Follow-up continued until December 31, 2007 . Complete details of the structure and methods of the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry have been reported elsewhere (19) .
The primary outcome measure was cardiovascular death after commencing dialysis. Cause of cardiovascular death was reported to the registry by the patient's attending nephrologist according to the following categories: myocardial ischemia/infarction, pulmonary edema, hypertensive cardiac failure, other cause of cardiac failure, cardiac arrest (cause uncertain), cerebrovascular accident, aortic aneurysm rupture, and bowel infarction. No information was collected regarding laboratory parameters, prescribed medications, percutaneous or surgical revascularizations, or other treatments used.
Results were expressed as frequencies and percentages for categorical variables and median (interquartile range) for continuous nonnormally distributed variables. Baseline analyses were carried out separately for presence or absence of CVD (coronary artery disease and/or cerebrovascular disease and/or peripheral vascular disease) at baseline. Differences between patients receiving PD or HD at first treatment (day 0) were analyzed by 2 There was no evidence of an interaction between modality and dialysis era, age, diabetes, country, or CVD. However there were significant interactions between modality and BMI and racial origin. Cumulative incidence was used to estimate probabilities of specific types of cardiovascular death, because this approach takes into account the presence of competing risks with deaths from other types of CVD. Nonoverlapping 95% confidence bands indicate a significant difference (at the 5% level) in cumulative incidence between the two treatment groups. Data were analyzed using Stata/IC 10 (Stata Corporation, College Station, TX). P values less than 0.05 were considered statistically significant.
Results

Baseline Characteristics
During the study period, a total of 24,587 adult patients commenced dialysis in Australia and New Zealand (first treatment PD n ϭ 6521; HD n ϭ 18,066). The total study follow-up was 66,005 person-years (PD 20,466 person-years; HD 45,539 person-years). Compared with patients starting dialysis on HD, patients starting on PD were more likely to be older, female, nonobese, treated in New Zealand, treated in larger centers, referred to a nephrologist more than 3 mo before commencing renal replacement therapy, and commenced on dialysis before 2002 (Table 1) . PD patients were also less likely to be a current smoker, have chronic lung disease, or be of Australian Aboriginal or Torres Strait Islander racial origin. Although PD patients were more likely to change modality at least once (Table 1) , patients commencing HD were more likely to change modality within the first 6 mo of treatment (19.5% versus 8.7%). Statistically significant differences were observed in comorbid illness burden between the two groups, although the magnitudes of these differences were small. The prevalence of automated PD use in PD patients during the study period was 16.1%. ). The incidence rates of cardiovascular mortality in PD and HD patients were 9.99 and 7.96 per 100 patient-years, respectively [unadjusted IRR PD versus HD 1.25, 95% CI 1.12 to 1.32]. The incidence rates of deaths from noncardiovascular causes in PD and HD patients were 7.50 and 6.80 per 100 patient-years, respectively (unadjusted IRR PD versus HD 1.10, 95% CI 1.04 to 1.17). When cumulative incidence functions were calculated for cardiovascular deaths, 95% confidence bands did not overlap after 2 yr, confirming that PD was associated with an increased risk of death from CVD after 2 yr of treatment (Figure 1 ). On competing risks multivariable Cox proportional hazards model anal- 
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Coronary artery disease ysis, the cause-specific hazard ratios of cardiovascular death and death from other causes between PD and HD were found to be nonconstant over time (i.e., nonproportional hazards). The proportional hazards assumption was also violated for presence of coronary artery disease, presence of cerebrovascular disease, late referral to a nephrologist, and current smoking status. To deal with nonproportional hazards, the follow-up period was divided into survival over the first year of treatment, between 1 and 4 yr of treatment, and after 4 yr of treatment. In each of these time periods, the proportional hazards assumption was verified and interaction terms between time on study and each of the covariates exhibiting nonproportional hazards were included in the model to obtain hazard ratios for each period of time. There were statistically significant interactions between modality and BMI and racial origin, so hazard ratios were calculated separately for each BMI and racial origin combination. Figure 2 shows the hazard ratios a Death outcomes are expressed as number (incidence rate per 100 patient-years). with 95% CI by BMI for nonindigenous patients. 
Causes of Cardiovascular Mortality
The causes of cardiovascular death are shown in Table 2 . In patients with CVD at baseline, cardiac failure and cardiac arrest were significantly more common causes of death in PD patients compared with HD patients (Table 3) . Death resulting from withdrawal from treatment due to cardiac disease was significantly less common in PD patients. Myocardial infarction/ ischemia was significantly more common in PD patients regardless of the presence of CVD at baseline (Table 3 ). There were no significant differences between PD and HD patients' incidence rates of other forms of cardiovascular death ( Table 3) .
The excess cardiovascular-specific mortality in PD patients was explained by an augmented risk of myocardial ischemia/ infarction ( Figure 3A) . Cumulative incidence of myocardial ischemia/infarction was increased in PD patients after 1 yr of treatment. The cumulative incidences of deaths from myocardial ischemia/infarction in PD and HD patients were 0.03 and 0.03 at 1 yr and 0.18 and 0.11 at 5 yr, respectively. There were no significant differences in cumulative incidences of cardiac arrest ( Figure 3B) ; nonhypertensive cardiac failure ( Figure 3C ); cerebrovascular accident ( Figure 3D) ; pulmonary edema; hypertensive cardiac failure; aortic aneurysm rupture; bowel infarction; or withdrawal from treatment due to cardiac, cerebrovascular, or peripheral vascular disease (data not shown).
Discussion
The study presented here demonstrated that the risk of death from CVD was significantly increased in PD patients compared with HD patients after the first year of treatment. Our findings are in keeping with those of previous publications (21) (22) (23) (24) , which have suggested poorer cardiovascular outcomes in PD patients. Bloembergen et al. (21, 22) analyzed the U.S. Renal Data System for prevalent dialysis patients (1987 to 1989) and observed a significantly increased mortality risk for PD compared with HD for all cause-of-death categories, except malignancy, for which there was a higher mortality risk for HD. The excess all-cause mortality observed in PD-treated patients was accounted for, in decreasing order, by infection (35%), acute myocardial infarction (24%), other cardiac causes (16%), cerebrovascular disease (8%), and withdrawal (8%). However, this study was significantly limited by the inclusion of prevalent patients, thereby raising the possibility of selective survival bias.
More recently, Ganesh et al. (23) used nonproportional Cox regression models to estimate the relative risk of death for U.S. patients with and without coronary artery disease by dialysis modality using intention to treat and as-treated approaches. They observed that patients with established coronary artery disease treated with PD had significantly poorer survival compared with HD. Using the same population of patients and the same analytical methods, Stack et al. (24) reported that new ESRD patients with a clinical history of congestive heart failure experienced poorer survival on PD compared with HD. Vonesh et al. (25) subsequently performed a U.S. Renal Data System analysis using a more recent cohort of patients with stratification for age and a general level of comorbidity rather than a specific comorbid condition. They observed that survival differences varied substantially over time between PD and HD according to age and baseline comorbidity. Nevertheless, all of the U.S. studies have been potentially limited by underreporting of comorbidity and other data commonly associated with Medical Evidence Form 2728 (18) , which may potentially vary (27) found no difference between PD and HD in the proportions of 433 incident dialysis patients who went on to develop new ischemic heart disease or cardiac failure while on dialysis treatment. Both of these studies were limited by lack of statistical power, lack of consideration of nonproportional hazards and competing risks, and uncertain relevance of outcomes observed over a decade ago to contemporary dialysis practice. The relevance to current practice is particularly important in view of observations that outcomes in PD patients have improved over time relative to those in HD patients (18, 28) .
Several other registry (29 -35) and prospective observational cohort studies (36 -39) have examined the effect of dialysis modality on patient outcomes, with generally conflicting results. These studies have been reviewed by Vonesh et al. (18) and have primarily focused on all-cause mortality rather than cardiovascular mortality. To date, most investigations have observed that PD patient outcomes are equivalent to or better than those for HD patients in the first 1 to 2 yr, but progressively worsen relative to HD thereafter. Our group has also observed this phenomenon for all-cause mortality (40) and infectious mortality (41) . A novel finding of the study presented here is that we have demonstrated for the first time that the increasing risk of all-cause mortality in PD versus HD over time also applies to cardiovascular mortality. The reasons for this observation are uncertain but may relate to the differential rate of residual renal function decline between PD and HD (13, 14, 42) ; the declining rates of dialysis catheter usage in HD patients after the first year (43) ; the increasing rate of infectious complications in PD patients relative to HD patients over time (41) ; or the greater propensity for PD patients to develop insulin resistance, dyslipidemia, and metabolic syndrome over time as a result of peritoneal exposure to glucose (16, 44) .
Because CVD is the major cause of death in dialysis populations, further studies are warranted to confirm whether cardiovascular mortality differs between PD and HD. The ideal vehicle for comparison is a randomized controlled trial. However, two previous attempts at such trials have been complicated by lack of statistical power (45) and poor recruitment (46) . Given that the feasibility of a definitive randomized controlled trial in this area is highly questionable, large observational studies are likely to offer the best available evidence, although they do not directly offer evidence of causality.
The strengths of our study include its very large sample size, use of contemporary incident patients, high PD penetration (41%), and robustness of findings across different statistical methodologies. We included all patients who began dialysis therapy in Australia or New Zealand over the time period; thus, various centers were included with varying approaches to use of dialysis modalities and varying rates of transplantation. This greatly enhanced the external validity of our findings.
Nevertheless, the study has several limitations. ANZDATA does not collect detailed information on PD or HD prescription, medication use (including vitamin D), patient compliance, nonfatal CVD, HD catheter use, hospitalizations, individual unit management protocols, laboratory values, residual urine output, or the severity of comorbidities, therefore unidentified associations cannot be entirely excluded. Although we adjusted for many patient characteristics, the possibility of residual confounding also cannot be excluded. Moreover, time-updated covariate data were not available for analysis. The results may also have been influenced by selection bias because the choice of dialysis modality was nonrandom. In common with other registries, ANZDATA is a voluntary registry and there is no external audit of data accuracy (including coding of the cause of death). Consequently, the possibility of coding/classification bias cannot be excluded (47) . Although we included all patients who commenced dialysis therapy as their first RRT modality, overall treated ESRD incidence rates in Australia are currently around 100 per million per year, substantially lower than the United States and slightly lower than many European countries, although broadly comparable with rates in other countries, such as Sweden, The Netherlands, and Poland (48) . Differences in the characteristics of patients might explain the differing results; alternatively, it might be that there are systematic differences in the treatment outcomes between countries. Although there are no published data that allow comparisons of PD mortality rates, there is substantial variation in HD mortality rates, which is not explained by measured comorbidities (49) .
The study presented here demonstrates that PD is associated with an increased risk of cardiovascular mortality compared with HD after the first year. This excess risk is due primarily to a heightened risk of myocardial ischemia/infarction, which increases with increasing time on dialysis. Although the increased risk of cardiovascular-related mortality in PD patients in our study should not be interpreted as an endorsement of HD over PD, these study findings should form part of the basis for informing shared decision-making about dialysis modality selection in conjunction with patient preference, individual circumstances, and the other well characterized pros and cons of selecting PD versus HD. Further attention to cardiovascular risk factor management in PD would also appear warranted.
